The foreign exchange eye APP news: trillion Chinese medicine health industry again welcomed the policy favor!
On October 27, the Chinese government network released the "State Council on the promotion of the inheritance of traditional Chinese medicine innovation and development of opinions" (Opinions), put forward a sound Chinese medicine service system, play a unique role in the maintenance and promotion of traditional Chinese medicine in people's health and other six major opinions.
On the one hand, the industry policy favor constantly, on the other hand, the industry is still insufficient innovation and other factors, some companies have begun to take action to actively transform. Chinese medicine industry performance differentiation is showing.
Six Opinions on Promoting the Development of Chinese Medicine
"Opinions" put forward the following six opinions, which focus on the following information:
A sound Chinese medicine service system
Great development of Chinese medicine clinics, outpatient clinics and specialty hospitals, and to encourage the chain operation. Clearly by 2022, the basic realization of the county-run Chinese medicine medical institutions full coverage, and strive to achieve all community health service centers and township health centers set up Chinese medicine hall, equipped with Chinese medicine practitioners. The implementation of "Internet + Chinese medicine health services" action.
Second, to give full play to the unique role of Chinese medicine in the maintenance and promotion of people's health
in about three years, screening 50 Chinese medicine treatment of advantageous types of diseases and 100 appropriate technology, 100 varieties of traditional Chinese medicines with unique curative effects, and timely release of the community. Focusing on cancer, cardiovascular and cerebrovascular diseases, diabetes, infectious diseases, Alzheimer's disease and antibiotic resistance, carry out collaborative research on Chinese and Western medicines, and by 2022, form and popularize 50 or so Chinese and Western medicines combined diagnostic and treatment programs.
Third, vigorously promote the quality of traditional Chinese medicine and the high-quality development of the industry
Revise the production quality management standards for traditional Chinese medicinal materials, and promote ecological planting of traditional Chinese medicinal materials, wild nurturing and biomimetic cultivation. Strengthen the protection of rare and endangered wild medicinal plants and animals, and support the research, development and utilization of rare and endangered herbal substitutes. Improve the pesticide residue and heavy metal limit standards for Chinese herbal medicines by region and species. The development of Chinese herbal medicine seedling management approach.
By 2022, basically establish a system of technical standards for the production of authentic medicinal herbs and a grade evaluation system. Accelerate the revision of the Chinese People's *** and State Pharmacopoeia Chinese medicine standards (a), by the State Council drug supervision and management department in conjunction with the Chinese medicine department in charge of the organization of experts to undertake the relevant work, the establishment of the most rigorous standards. Improve the standard system for Chinese medicine tablets, and formulate and implement national standards for the preparation of Chinese medicine tablets. Implementing a priority review and approval system based on clinical value. Establish a multi-sectoral collaborative regulatory mechanism, explore the establishment of Chinese herbal medicines, Chinese medicinal tablets, pCms production, circulation and use of the whole process of traceability system, in about five years, and gradually realize the key varieties of traditional Chinese medicine can be traced, the destination can be traced, the responsibility can be investigated.
Fourth, strengthen the construction of Chinese medicine talent
National major talent projects, academician selection to increase support for Chinese medicine talent, research in the Chinese Academy of Engineering Department of Medicine and Health set up a separate group of Chinese medicine. Study the establishment of Chinese medicine talent recognition and reward system, strengthen the national Chinese medicine inheritance and innovation recognition, the establishment of Chinese medicine industry recognition of long-term mechanism, focusing on the discovery and promotion of young and middle-aged backbone talents and inheritors.
V. Promote the development of Chinese medicine inheritance and open innovation
Construction of national key laboratories in key areas of Chinese medicine, the establishment of a number of national clinical medical research centers, national engineering research centers and technology innovation centers. Carry out clinical research on the prevention and treatment of major, intractable and rare diseases and new outbreaks of infectious diseases, accelerate the research on the creation and manufacture of new Chinese medicines, and research and develop a number of advanced Chinese medicine devices and Chinese medicine pharmaceutical equipment. Support to encourage innovative research and development of proprietary Chinese medicines for children.
Sixth, reform and improve the management system and mechanism of traditional Chinese medicine
Improve the health insurance payment method in line with the characteristics of traditional Chinese medicine. The system of coding for the categorization of Chinese medicine illnesses and diseases has been improved in conjunction with the International Classification of Diseases. Timely incorporation of qualified TCM medical institutions into the designated medical institutions for medical insurance; active incorporation of appropriate TCM medical service programs and Chinese medicines into the scope of medical insurance in accordance with the regulations. The study of the abolition of the increase in the proportion of Chinese medicine drinks related work.
Chinese medicine big health industry in 2020 will exceed 3 trillion
2016, can be said to be the Chinese medicine industry's policy year, the national strategic development plan, namely, "Outline of the Strategic Plan for the Development of Traditional Chinese Medicine (2016-2030)" (referred to as the "Plan") and other heavyweight documents were released in that year, from the many aspects to encourage and support the development of the industry, including cultivation, circulation, terminal services and other areas, all with standardized opinions. Among them, the "Plan" proposed to strive for "by 2020, the realization of the basic enjoyment of Chinese medicine services for all; by 2030, the Chinese medicine service area to achieve full coverage".
In recent years, the state has introduced many favorable policies to provide fertile soil for the development of Chinese medicine. Data show that since the issuance of the national strategic development plan in 2016, the gap between the growth rate of diagnosis and treatment volume of Chinese medicine hospitals and Western medicine hospitals has narrowed over the past three years and reversed in 2018, with the growth rate of diagnosis and treatment volume of Chinese medicine hospitals increasing by 4.4% in 2018, and that of Western medicine by 4.0%.
With China's rapid social and economic development, the living standards of urban and rural people are constantly improving, and in recent years, the rural urbanization process has accelerated, the overall health demand has increased significantly, the people's awareness of health care has generally increased, and the demand for health care products is increasingly strong. On the other hand, China's population is rapidly aging, and a large number of elderly people with spending power are bound to boost demand in the healthcare market.
CICC believes that the promotion of national health awareness will continue to drive the development of the "treatment" market, which is more of an incremental market, but also more of a self-funded market, originating from the demand for health from the demand for treatment to preventive demand, and further extension of the health care market, which is a development opportunity only at a certain stage of the development of the society (health awareness and willingness to pay). This is a development opportunity only at a certain stage of social development (health awareness and willingness to pay at the same time), and traditional Chinese medicine has a natural advantage in the "treatment of the future" market.
Great Wall Securities believes that in recent years, the state has launched a number of policies to continuously standardize the development of traditional Chinese medicine, encourage the comprehensive development and utilization of Chinese medicine resources and research and development of new medicines, to enhance the capacity of traditional Chinese medicine services, and promote the construction of a healthy China. China's Chinese medicine industry is developing rapidly, with the market size growing from 557.4 billion yuan in 2012 to 880.5 billion yuan in 2016, with a compound annual growth rate of 9.58%. With the continuous release of policy dividends, seize the strategic opportunity of supply-side structural reform to promote the revitalization and development of Chinese medicine, ushering in a new opportunity for the development of the Chinese medicine sector.
China Business Industry Research Institute believes that in the past seven years, the market size of China's traditional Chinese medicine health industry has continued to rise, maintaining double-digit high growth. According to the white paper "Chinese medicine in China" released by the State Council Information Office, by 2020, China's traditional Chinese medicine industry will exceed 3 trillion dollars, and the average annual compound growth rate will remain at 20%. It can be seen that the future of China's traditional Chinese medicine industry has a strong potential development space.
Four Chinese medicine companies doubled their performance in the third quarter
In recent years, China's reform and development of Chinese medicine has made remarkable achievements. But the lack of innovation and other factors, the impact of the listed companies in the development of Chinese medicine is not enough power, performance has been under pressure. In the face of this situation, some Chinese medicine enterprises, especially the old enterprises have been actively seeking transformation.
For example, Yunnan Baiyao, Guangzhou Pharmaceutical Group under the Baiyunshan and other enterprises have acted mainly through the integration and reorganization of assets, equity incentives, as well as mixed ownership reform to improve profitability. Among them, Baiyunshan performance growth rate is more obvious. 2016-2018, the company's net profit attributable to the year-on-year growth rate of 15.97%, 36.71% and 66.9%.
On the whole, the performance of Chinese medicine companies has also diverged.
Flush statistics show that the A-share listed companies of Chinese medicine *** count 67. As of October 27, 31 listed Chinese medicine companies have released their third quarterly reports. Among them, Tai Long Pharmaceuticals, Taihealth, Dali Pharmaceutical and Ma Yinglong four listed Chinese medicine companies in the first three quarters of the year-on-year growth rate of net profit attributable to shareholders of the parent company were more than 140%. Among them, Tai Lung Pharmaceutical topped the list, with a year-on-year increase in net profit attributable to parent company shareholders of 483.9%.
The 2019 half-year report previously released by Tai Long Pharmaceutical shows that the company's net profit attributable to mother in the first half of the year increased by 848.78% year-on-year. In this regard, the company said that during the reporting period, the company's revenue structure adjustment, in the case of significant compression of the drug distribution business, the drug preparation business, Chinese medicine beverage business, drug research and development services and other major businesses continue to expand, leading to an increase in the overall operating income; and with the divestment of some of the loss-making assets, the company's net profit has increased significantly compared to the same period of the previous year; with the adjustment and expansion of the scale of operation, the company's operating assets have increased, resulting in a With the adjustment and expansion of the scale of operation, the company's operating assets increased, resulting in an increase in cash outflow from operating activities.
Tai Long Pharmaceutical in the background of last year's performance of a sharp decline in performance, this year's results will be profitable. The company's three-quarterly report shows that the net profit of 2018 is negative, and the scale of the company's pharmaceutical manufacturing and drug research and development business is expanding in the 1-3 quarter of 2019, and the operating results are growing; at the same time, some of the loss-making assets have been divested, and it is expected that the company will be profitable for the whole year.
The data show that there are another 8 listed Chinese medicine companies, such as Kun Medicine Group, the net net profit of the third quarter increased by more than 10%. Of course, there are some companies performance growth has slowed down. The data show that there are 12 companies such as Longjin Pharmaceuticals net profit growth rate has declined. Among them, Longjin Pharmaceuticals net profit growth rate declined the most, amounting to 87.57%.
Longjin Pharmaceuticals previously released three-quarter results forecast put forward, the reporting period, due to the national health insurance fee control, prescription restrictions and other policies continue to promote, the company part of the sales region, sales terminal sales decline, resulting in a decline in operating income, net profit decreased. Government grants and financial products received during the reporting period compared to the same period last year, there is a certain degree of decline, so it led to a substantial decline in net profit.